News Briefs

Premium

Mt. Sinai Spinout Vivaldi Biosciences Nets $23M in Startup Financing

Influenza vaccine developer Vivaldi Biosciences, a spinout of the Mount Sinai School of Medicine in New York, said this week that it has received commitments for $23 million in Series A financing, of which $18.85 million has been funded.

Bay City Capital and NGN Capital co-led the financing, with participation by the New York City Investment Fund and Alexandria Real Estate Equities. The remaining commitments are to be funded subject to achievement of certain milestones, Vivaldi said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.